格隆汇1月22日丨复星医药(600196.SH)公布，近日，本公司控股子公司锦州奥鸿药业有限责任公司就重 酒石酸去甲肾上腺素注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于急性低 血压状态的血压恢复；也可用于心跳骤停的辅助治疗和心跳骤停复苏后的血压维持；对血容量不足导致 的休克，本品作为急救时补充血容量的辅助治疗，以使血压回升，暂时维持脑与冠状动脉灌注，直到补 充血容量治疗发生作用。 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-009 上海复星医药（集团）股份有限公司 关于分拆子公司上市的一般风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 1 月 22 日，上海复星医药（集团）股份有限公司（以下简称"本公司"） 召开第十届董事会第二十二次会议，会议审议通过拟分拆所属子公司复星安特金（成 都）生物制药股份有限公司（以下简称"复星安特金"）至香港联合交易所有限公 司（以下简称"香港联交所"）主板上市（以下简称"本次分拆上市"或"本次分 拆"）的相关议案。本次分拆完成后，预计不会影响本公司对复星安特金的控制权。 详情请见同日刊登于《中国证券报》《上海证券报》《证券时报》和上海证券交易 所网站（https://www.sse.com.cn）的相关公告。 1、如本次分拆事项预案披露前本公司 A 股股票交易存在明显异常，可能存在因 涉嫌内幕交易被立案调查，导致本次分拆被暂停、终止的风险。 2、本次分拆上市尚需满足多项条件方可实施，包括但不限于取得本公司股东会、 A 股类 ...

上海市方达律师事务所 关于上海复星医药（集团）股份有限公司 分拆复星安特金（成都）生物制药股份有限公司 至香港联合交易所有限公司主板上市的 法律意见书 2026 年 1 月 | 一、本次分拆的批准和授权 | 6 | | --- | --- | | （一）本次分拆已取得的批准和授权 6 | | | （二）本次分拆尚需取得的批准和授权 6 | | | 二、本次分拆上市的主体资格 | 7 | | （一）公司是依法设立的股份有限公司 7 | | | （二）公司是有效存续的上市公司 7 | | | 三、本次分拆上市的实质条件 | 8 | | （一）上市公司符合《分拆规则》第三条规定的条件 9 | | | （二）上市公司不存在《分拆规则》第四条规定的不得分拆的情形 12 | | | （三）上市公司所属子公司不存在《分拆规则》第五条规定的不得分拆的情形 14 | | | 四、本次分拆上市的相关事项核查 | 17 | | （一）上市公司已对《分拆规则》第六条规定的事项进行充分说明并披露 17 | | | （二）本次分拆符合相关法律法规和《分拆规则》 19 | | | （三）本次分拆有利于维护股东和债权人合法权益 19 | | ...

之 独立财务顾问核查意见 中国国际金融股份有限公司 关于 上海复星医药（集团）股份有限公司 分拆所属子公司 复星安特金（成都）生物制药股份有限公司 至香港联合交易所有限公司主板上市 独立财务顾问 二〇二六年一月 | 录 目 | 1 | | --- | --- | | 释 义 | 2 | | 一、本次分拆符合《分拆规则》相关要求 | 3 | | （一）上市公司符合《分拆规则》第三条规定的分拆条件 3 | | | （二）上市公司不存在《分拆规则》第四条规定的不得分拆情形 6 | | | （三）上市公司所属子公司不存在《分拆规则》第五条规定的不得分拆情形 7 | | | （四）《分拆规则》第六条规定的上市公司应当充分披露并说明事项 8 | | | 二、本次分拆符合相关法律、法规的规定 | 12 | | 三、本次分拆上市有利于维护上市公司股东和债权人的合法权益 13 | | | 四、上市公司分拆后能够保持独立性及持续经营能力 | 13 | | 五、复星安特金具备相应的规范运作能力 | 14 | | 六、本次分拆履行的法定程序完备、合规，提交的法律文件有效 14 | | | 七、上市公司披露的相关信息不存在虚假记载、误 ...

复星医药公告称，拟分拆子公司复星安特金至港交所主板上市。2026年1月22日公司召开董事会审议通 过相关议案，核查2025年12月23日至2026年1月21日（董事会决议日前20个交易日）公司A股价格波动 情况，该区间内复星医药A股累计涨幅0.66%，剔除同期上证指数、上证医药指数涨跌幅后，分别 为-4.43%和-0.80%，均未超20%，未构成异常波动情形。 ...

复星医药公告，公司控股子公司锦州奥鸿药业有限责任公司就重酒石酸去甲肾上腺素注射液的药品注册 申请获国家药品监督管理局批准。该药品获批适应症包括急性低血压状态的血压恢复、心跳骤停的辅助 治疗和心跳骤停复苏后的血压维持等。该药品为复星医药自主研发的化学药品，截至2025年12月，累计 研发投入约为人民币874万元。根据IQVIA CHPA数据，2024年该药品在中国境内的销售额约为人民币 18.11亿元。 ...

Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector has experienced a decline of 0.85%, ranking among the top losers in the concept sector, with companies like Delong Huineng, Rundu Co., and Kunming Pharmaceutical Group showing significant declines [1] Group 2 - The top gainers in today's concept sectors include Lead Metal with a rise of 5.01%, Zinc Metal at 4.83%, and Gold Concept at 3.82%, while the top losers include Duty-Free Shops at -1.16% and Trust Concept at -1.09% [2] - The net outflow of main funds from the Artemisinin concept sector today was 0.24 billion yuan, with six stocks experiencing net outflows, led by Delong Huineng with a net outflow of 36.54 million yuan [2] - The stocks with the highest net inflows include Fosun Pharma, New Hecheng, and Zhejiang Medicine, with net inflows of 32.34 million yuan, 19.09 million yuan, and 9.40 million yuan respectively [2]

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials for HLX701 in combination with Cetuximab and chemotherapy for the treatment of advanced colorectal cancer [1] Group 1 - The approved drug, HLX701, is a recombinant human SIRPα-IgG4Fc fusion protein injection [1] - The clinical trials will be conducted in China once conditions are met [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. has received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials for HLX701 in combination with Cetuximab and chemotherapy for advanced colorectal cancer [1] Group 1: Company Developments - The clinical trials for HLX701 will be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan, once conditions are met [1] - HLX701 was introduced by Fuhong Hanlin in June 2025 and has exclusive licensing rights for development, production, and commercialization in specified regions including mainland China, Hong Kong, Macau, and certain Southeast Asian, Middle Eastern, and North African countries [1]